ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Dual-Delivery System Designed to Overcome EV-Mediated Ferroptosis Resistance for Efficient Solid Tumor Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Tumor-derived extracellular vesicles (EVs) are emerging as critical mediators of metabolic adaptation, yet their role in orchestrating ferroptosis resistance within the tumor microenvironment remains poorly understood. Here, we show that highly malignant osteosarcoma (OS) cells respond to ferroptotic stress by secreting EVs enriched with Alpha-enolase (ENO1). These EVs-ENO1 not only bolster the antioxidant capacity of tumor cells but also confer widespread ferroptosis resistance to macrophages and neutrophils, fostering an immunosuppressive niche. To disrupt this metabolic defense, we developed an OS-targeting lipid nanoparticle (LNP) system for the synergistic delivery of BAP1 mRNA and ENO1 siRNA. We demonstrate that this dual-delivery platform enhances ferroptosis through two complementary regulatory pathways, BAP1/SLC7A11 and ENO1/GPX4, leading to potent lipid peroxidation and tumor cell death. In syngeneic orthotopic and lung metastasis models, these targeted LNPs significantly suppress tumor progression and catalyze anti-tumor immunity by activating M1-type macrophages and cytotoxic T cells. Our findings identify the secretion of EVs-ENO1 as a key reactive mechanism against ferroptosis and provide a translatable nanomedicine strategy to overcome metabolic and epigenetic resistance in solid tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.